These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34625085)

  • 1. Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis.
    Tiemersma EW; Ali I; Alemu A; Avong YK; Duga A; Elagbaje C; Isah A; Kay A; Mmbaga BT; Mmari E; Mwamwitwa K; Nhlabatsi S; Sintayehu K; Arefayne A; Teferi M; Cobelens F; Härmark L
    BMC Health Serv Res; 2021 Oct; 21(1):1062. PubMed ID: 34625085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
    Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
    Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.
    Tiemersma E; van den Hof S; Dravniece G; Wares F; Molla Y; Permata Y; Lukitosari E; Quelapio M; Aung ST; Aung KM; Thuy HT; Hoa VD; Sulaimanova M; Sagyndikova S; Makhmudova M; Soliev A; Kimerling M
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31604816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacovigilance guidelines in the Southern African Development Community: A document review.
    Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
    Pharmacoepidemiol Drug Saf; 2024 Feb; 33(2):e5755. PubMed ID: 38362654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-Term Training, a Useful Approach for Sustainable Pharmacovigilance Knowledge Development in Tanzania, Kenya, Ethiopia and Rwanda.
    van Puijenbroek E; Barry A; Khaemba C; Ntirenganya L; Gebreyesus TD; Fimbo A; Minzi O; Makonnen E; Oluka M; Guantai A; Aklillu E
    Drug Saf; 2024 Dec; 47(12):1193-1202. PubMed ID: 39162987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development, assessment and educational impact of a blended e-learning training program on pharmacovigilance implemented in four African countries.
    Schievano F; Mwamwitwa KW; Kisenge S; Mmari E; Duga A; Nhlabatsi S; Elagbaje C; Abiola AS; Meshesha SG; Pagani S; Lora R; Sabaini A; Cobelens F; Härmark L; Eko EB; Conforti A; Venegoni M; Magro L; Moretti U
    Front Med (Lausanne); 2024; 11():1347317. PubMed ID: 38695021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors contributing to drug-resistant tuberculosis treatment outcome in five countries in the Eastern Europe and Central Asia region.
    Auer C; Mazitov R; Makhmudov A; Pirmahmadzoda B; Skrahina A; Dobre A; Sécula F; Bosch-Capblanch X; Van den Boom M; Migliori GB; Mdivani N; Yassin MA
    Monaldi Arch Chest Dis; 2020 Mar; 90(1):. PubMed ID: 32231347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
    Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
    Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
    Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
    Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania.
    Barry A; Olsson S; Khaemba C; Kabatende J; Dires T; Fimbo A; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; van Puijenbroek E; Bergman U; Nkayamba A; Mugisha M; Gurumurthy P; Aklillu E
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33671293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pragmatic Management of Drug-Resistant Tuberculosis: A Qualitative Analysis of Human Resource Constraints in a Resource-Limited Country context-Ethiopia.
    Mussie KM; Gradmann C; Yimer SA; Manyazewal T
    Int J Public Health; 2021; 66():633917. PubMed ID: 34434083
    [No Abstract]   [Full Text] [Related]  

  • 12. Exploring local realities: Perceptions and experiences of healthcare workers on the management and control of drug-resistant tuberculosis in Addis Ababa, Ethiopia.
    Mussie KM; Yimer SA; Manyazewal T; Gradmann C
    PLoS One; 2019; 14(11):e0224277. PubMed ID: 31721767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Setting up pharmacovigilance based on available endTB Project data for bedaquiline.
    Lachenal N; Hewison C; Mitnick C; Lomtadze N; Coutisson S; Osso E; Ahmed S; Leblanc G; Islam S; Atshemyan H; Nair P; Kholikulov B; Aiylchiev S; Zarli K; Adnan S; Krisnanda A; Padayachee S; Stambekova A; Sahabutdinova Y; de Guadalupe S; Moreno P; Kumsa A; Reshid A; Makaka J; Abebe S; Melikyan N; Seung KJ; Khan U; Khan P; Huerga H; Rich M; Varaine F
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1087-1094. PubMed ID: 33126944
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment interruption and associated factors among patients registered on drug-resistant tuberculosis treatment in Amhara regional state, Ethiopia: 2010-2017.
    Merid MW; Muluneh AG; Yenit MK; Kassa GM
    PLoS One; 2020; 15(10):e0240564. PubMed ID: 33052983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance systems in developing countries: an evaluative case study in Burkina Faso.
    Kabore L; Millet P; Fofana S; Berdai D; Adam C; Haramburu F
    Drug Saf; 2013 May; 36(5):349-58. PubMed ID: 23580195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National medicines regulatory authorities financial sustainability in the East African Community.
    Ndomondo-Sigonda M; Miot J; Naidoo S; Ng'andu B; Ngum N; Masota NE; Kaale E
    PLoS One; 2020; 15(7):e0236332. PubMed ID: 32702048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.
    Lukoye D; Ssengooba W; Musisi K; Kasule GW; Cobelens FG; Joloba M; Gomez GB
    BMC Public Health; 2015 Mar; 15():291. PubMed ID: 25880829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa.
    Stegmann JU; Jusot V; Menang O; Gardiner G; Vesce S; Volpe S; Ndalama A; Adou F; Ofori-Anyinam O; Oladehin O; Mendoza YG
    BMC Public Health; 2022 Aug; 22(1):1568. PubMed ID: 35978276
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.